GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal

Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.

More from Archive

More from Pink Sheet